Cellectis Logo

Cellectis

Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.

ALCLS | PA

Overview

Corporate Details

ISIN(s):
FR0010425595 (+2 more)
LEI:
5493000KKX5VQ37Q2W83
Country:
France
Address:
8 RUE DE LA CROIX JARRY, 75013 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellectis is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. The company leverages its proprietary TALEN® gene-editing technology to engineer Chimeric Antigen Receptor (CAR) T-cells from healthy donors. This creates allogeneic, or "off-the-shelf," product candidates designed for broad patient accessibility, providing a scalable alternative to individualized autologous therapies. Cellectis' platform aims to solve key challenges in allogeneic cell therapy, such as Graft-versus-Host Disease (GvHD) and host rejection, while integrating safety features. The company possesses a strong intellectual property portfolio and collaborates with global strategic partners to advance its therapeutic pipeline.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-05 22:30
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total des droits de vote et d’actions …
French 83.2 KB
2025-06-05 22:30
Declaration of Voting Results & Voting Rights Announcements
Monthly information on share capital and company voting rights
English 84.7 KB
2025-05-21 22:30
Pre-Annual General Meeting Information
L’Assemblée Générale Mixte de Cellectis se tiendra le 26 juin 2025
French 44.7 KB
2025-05-21 22:30
Pre-Annual General Meeting Information
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
English 84.0 KB
2025-05-12 22:30
Earnings Release
Cellectis publie ses résultats financiers du premier trimestre 2025
French 232.9 KB
2025-05-12 22:30
Earnings Release
Cellectis Reports Financial Results for the First Quarter 2025
English 216.6 KB
2025-05-07 22:30
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total des droits de vote et d’actions …
French 83.3 KB
2025-05-07 22:30
Declaration of Voting Results & Voting Rights Announcements
Monthly information on share capital and company voting rights
English 84.8 KB
2025-05-06 22:30
Report Publication Announcement
Cellectis publiera ses résultats financiers du premier trimestre le 12 mai 2025
French 67.7 KB
2025-05-06 22:30
Report Publication Announcement
Cellectis to Report First Quarter Financial Results on May 12, 2025
English 77.3 KB
2025-04-28 22:39
Regulatory News Service
Cellectis présente une approche non virale d’édition du génome et des innovatio…
French 190.3 KB
2025-04-28 22:30
Regulatory News Service
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the AS…
English 75.1 KB
2025-04-07 22:30
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total des droits de vote et d’actions …
French 122.2 KB
2025-04-07 22:30
Declaration of Voting Results & Voting Rights Announcements
Monthly information on share capital and company voting rights
English 91.5 KB
2025-03-13 23:46
Annual Report
Cellectis publie ses résultats financiers du quatrième trimestre 2024 et de l’e…
French 250.5 KB

Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectis

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectis via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.